De verborgen gevaren van vaccinaties - WantToKnow.nl

led the way in researching “bird-flu” vaccines, but now they are leading the way in other
virulent killer virus research. See http://www.avibio.com/biodefense-program.php. and
http://www.avibio.com/rna-therapeutics.php. [...]
Ik opende meteen het laatste van de twee genoemde bestanden en de inhoud daarvan was zo
interessant dat ik die hieronder in zijn geheel laat volgen:
[…] How RNA Therapeutics Work
Using modern methods of chemical synthesis, AVI makes compounds that bind selectively to
RNA, the carrier of genetic information from DNA to protein, and prevent production of a
particular protein. If this protein is needed for a virus infection or causes a disease, e.g.
cancer, the disease may be prevented or treated. AVI BioPharma is an early pioneer of
antisense technology, the precursor of the growing field of RNA therapeutics.
RNA-based therapeutic compounds are made up of subunits or monomers, linked together
and called oligomers. Each subunit carries a genetic “letter” or base (A, T, G or C) that
allows it to pair with its complementary monomer on the RNA target (A pairs with T and G
with C). The order of sequence of these “letters” determines the identity of the RNA to which
it binds, as well as the precise position in the sequence of the RNA that it seeks out
specifically. When the target is mRNA, which translates genetic information in protein, AVI
compounds are called Translation Suppressing Oligomers or TSO’s. AVI oligomers can also
be targeted to a pre-mRNA, which is not yet mature and needs to be processed and spliced to
make mRNA. Used in this capacity, AVI compounds are called Splice Switching Oligomers or
SSO’s because they can determine which – of several choices – mRNA is actually made
preferentially.
Genetic letters and base pairing are common to all RNA therapeutics, but chemists can
change the chemical character of the therapeutics molecules in subtle but significant ways.
For example, the fine structure and charge of the monomers determines the strenght of the
linkages that hold them to their target, the “backbone”of the oligomers can be altered to
achieve different properties, such as resistance to enzymic degradation or bioavailability.
The older antisense compound, and also siRNA, are designed to degrade their target RNA
molecules. Instead, AVI oligomers with morpholino backbone act by “steric blocking” –
binding to a target sequence within the RNA molecule and simply obstructing other
molecules that might otherwise interact with the RNA. Thus, there is no degadation of the
drug or its target mRNA […]
Hier staat dus beschreven wat ik eerder ook al betoogde over de uitwerking van het elektronegatieve
aluminium. Door de ‘lading’ van dit elektro-actieve element wordt de onderlinge
binding van atomen geregeld en daarmee ook de vouwing – ofwel de ruimtelijke structuur –
van moleculen bepaald. Dit is precies wat de wetenschapper Van der Waals al in de eerste
helft van de 20 ste eeuw uitvond.
Door de met behulp van ladingveranderende monomeren veranderde ruimtelijke structuur van
de beschreven kunstmatige moleculen kunnen deze moleculen nu verhinderen dat de daarvoor
bedoelde moleculen worden geblokkeerd en onwerkzaam worden. Als hun plek al wordt bezet
door een ‘stereo-isomere’ – dus qua ruimtelijke structuur veranderde – molecuul, dan krijgen
de natuurlijke moleculen geen kans meer. Hun stoel is dan al bezet.
In het eerstgenoemde bestand – Biodefense Program – staat deze werkwijze nog een keer
duidelijk genoemd:
63